GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kane Biotech Inc (OTCPK:KNBIF) » Definitions » EV-to-FCF

KNBIF (Kane Biotech) EV-to-FCF : -3.57 (As of Dec. 15, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Kane Biotech EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Kane Biotech's Enterprise Value is $11.92 Mil. Kane Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-3.34 Mil. Therefore, Kane Biotech's EV-to-FCF for today is -3.57.

The historical rank and industry rank for Kane Biotech's EV-to-FCF or its related term are showing as below:

KNBIF' s EV-to-FCF Range Over the Past 10 Years
Min: -34.93   Med: -4.58   Max: -1.02
Current: -3.87

During the past 13 years, the highest EV-to-FCF of Kane Biotech was -1.02. The lowest was -34.93. And the median was -4.58.

KNBIF's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 8.19 vs KNBIF: -3.87

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-15), Kane Biotech's stock price is $0.08. Kane Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $0.034. Therefore, Kane Biotech's PE Ratio (TTM) for today is 2.35.


Kane Biotech EV-to-FCF Historical Data

The historical data trend for Kane Biotech's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kane Biotech EV-to-FCF Chart

Kane Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.80 -4.68 -8.96 -6.20 -9.94

Kane Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.68 -9.94 -11.03 -4.49 -4.63

Competitive Comparison of Kane Biotech's EV-to-FCF

For the Biotechnology subindustry, Kane Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kane Biotech's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kane Biotech's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Kane Biotech's EV-to-FCF falls into.



Kane Biotech EV-to-FCF Calculation

Kane Biotech's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=11.918/-3.337
=-3.57

Kane Biotech's current Enterprise Value is $11.92 Mil.
Kane Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kane Biotech  (OTCPK:KNBIF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Kane Biotech's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.08/0.034
=2.35

Kane Biotech's share price for today is $0.08.
Kane Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.034.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Kane Biotech EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Kane Biotech's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Kane Biotech Business Description

Traded in Other Exchanges
Address
290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The Company has a separate operating segment for its Stem Animal Health subsidiary, which operates the animal health business. The firm is also engaged in the animal health business through its Stem Animal Health subsidiary.